Tasly Pharmaceutical Group Co (SHSE:600535) Net Income (Continuing Operations) : ¥1,048 Mil (TTM As of Mar. 2024)

View and export this data going back to 2002. Start your Free Trial

What is Tasly Pharmaceutical Group Co Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Tasly Pharmaceutical Group Co's Net Income (Continuing Operations) for the three months ended in Mar. 2024 was ¥293 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥1,048 Mil.

Tasly Pharmaceutical Group Co Net Income (Continuing Operations) Historical Data

The historical data trend for Tasly Pharmaceutical Group Co's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tasly Pharmaceutical Group Co Net Income (Continuing Operations) Chart

Tasly Pharmaceutical Group Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income (Continuing Operations)

Get a 7-Day Free Trial

1,003.17

1,089.86

2,407.62

-348.46

1,016.64

Tasly Pharmaceutical Group Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Income (Continuing Operations)	Get a 7-Day Free Trial															261.16	425.66	313.50	16.32	293.01

Tasly Pharmaceutical Group Co Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1,048 Mil.

Tasly Pharmaceutical Group Co (SHSE:600535) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Tasly Pharmaceutical Group Co Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Tasly Pharmaceutical Group Co's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

Tasly Pharmaceutical Group Co (SHSE:600535) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tasly Pharmaceutical Group Co Ltd (SHSE:600535) » Definitions » Net Income (Continuing Operations)

Traded in Other Exchanges

N/A

Address

2 Pujihe Road East, Beichen District, Tasly TCM Garden, Tianjin, CHN, 300410

Website

http://www.tasly.com

Tasly Pharmaceutical Group Co Ltd is a China-based company engaged in the manufacturing and distribution of pharmaceutical products. Its herbal medicines include Tasly Cerebral Care Granules and Tasly ICP. Its chemical medicines comprise of Ketotifen Fumarate Tablets, Thiamphenicol Capsules, Glucurolactone Tablets and Sulpiride Tablets. Some of the other products offered by the company include PharmceuticalSubstances & API, HerbalExtract, and Concentrated Herbal Granules.

Tasly Pharmaceutical Group Co (SHSE:600535) Headlines

No Headlines